Walter Ernst Kaufmann MD
Adult Congenital Heart Disease, Cardiac Electrophysiology
Physician
Join to view full profile
161 E Main St# CommunitPort Jervis, NY 12771
Phone+1 845-858-2666
Fax+1 845-858-2662
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Walter Kaufmann, MD is a cardiologist in Port Jervis, New York. He is currently licensed to practice medicine in New York and New Jersey. He is affiliated with Bon Secours Community Hospital.
Education & Training
Rutgers Health/Newark Beth Israel Medical CenterFellowship, Cardiovascular Disease, 1980 - 1982
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1977 - 1980- Rutgers New Jersey Medical SchoolClass of 1977
Certifications & Licensure
NJ State Medical License Current
NY State Medical License 1982 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Publications & Presentations
PubMed
- 188 citationsAutism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.Walter E. Kaufmann, Sharon A. Kidd, Howard Andrews, Dejan B. Budimirovic, Amy Esler
Pediatrics. 2017-06-01
Press Mentions
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (Blarcamesine) in Rett SyndromeNovember 6th, 2019
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27th, 2019- Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results and Provides Clinical Study UpdatesMarch 28th, 2019
